Wink Biotherapeutics develops precision therapeutics for Type 1 Diabetes and solid tumors using a proprietary platform of chemically modified RNA aptamers. These aptamers offer high‑affinity, low‑immunogenic target binding and can be engineered as antagonists, agonists, or delivery vehicles, enabling safer and more effective treatments. The platform supports rapid design and scalable, cell‑free manufacturing for pharmaceutical partners and research groups.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for Type 1 Diabetes and many solid tumors rely on broad‑acting drugs or biologics that can cause off‑target effects, limited efficacy, and significant safety concerns. The lack of highly specific, programmable therapeutics hampers the ability to intervene early or achieve durable disease modification.
Solution
Wink Biotherapeutics leverages a proprietary modified RNA aptamer platform to create precision therapeutics that bind selectively to disease‑relevant targets in Type 1 Diabetes and solid tumors. By chemically stabilizing RNA aptamers, the company produces molecules with high affinity, low immunogenicity, and enhanced serum half‑life. These aptamers can be engineered to modulate immune pathways, block pathogenic receptors, or deliver functional payloads directly to diseased cells. The approach enables rapid design cycles and scalable manufacturing, aiming to deliver safer, more effective treatments that address the underlying biology of both autoimmune diabetes and cancer.
Target Audience
Primary customers are pharmaceutical and biotech companies developing therapies for Type 1 Diabetes and solid tumor oncology, as well as academic research groups seeking high‑specificity RNA‑based tools.
Features
- Chemically modified RNA aptamers with nuclease resistance and extended circulation time
- High‑affinity target binding achieved through in‑vitro selection (SELEX) and iterative optimization
- Platform flexibility to generate antagonists, agonists, or targeted delivery vehicles for diverse disease mechanisms
- Low immunogenic profile compared with protein‑based biologics, reducing risk of adverse immune reactions
- Scalable, cell‑free synthesis process that supports rapid candidate generation and manufacturing